{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T23:13:34Z","timestamp":1794438814975,"version":"4.9.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T00:00:00Z","timestamp":1627862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T00:00:00Z","timestamp":1627862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Children living with human immunodeficiency virus (HIV) infection require lifelong effective antiretroviral therapy (ART). The goal of ART in HIV-infected persons is sustained viral suppression. There is limited information on virological non-suppression or failure and its associated factors in children in resource limited countries, particularly Ghana.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A cross-sectional study of 250 children aged 8\u2009months to 15\u2009years who had been on ART for at least 6\u2009months attending the Paediatric HIV clinic at Korle Bu Teaching hospital in Ghana was performed. Socio-demographic, clinical, laboratory and ART Adherence related data were collected using questionnaires as well as medical records\u00a0review. Blood samples were obtained for viral load and CD4\n                      <jats:sup>+<\/jats:sup>\n                      count determination. Viral load levels &gt;\u20091000 copies\/ml on ART was considered virological non-suppression. Logistic regression was used to identify factors associated with virological non-suppression.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The mean (\u00b1SD) age of the study participants was 11.4\u2009\u00b1\u20092.4\u2009years and the proportion of males was 53.2%. Of the 250 study participants, 96 (38.4%) had virological non-suppression. After adjustment for significant variables, the factors associated with non-suppressed viral load were female gender (AOR 2.51 [95% CI 1.04\u20136.07],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.041), having a previous history of treatment of tuberculosis (AOR 4.95 [95% CI 1.58\u201315.5],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.006), severe CD4 immune suppression status at study recruitment (AOR 24.93 [95% CI 4.92\u2013126.31],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and being on a nevirapine (NVP) based regimen (AOR 7.93 [95% CI 1.58\u20131.15],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.005).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The prevelance of virological non-suppression was high. Virological non-suppression was associated with a previous history of TB treatment, female gender, severe CD4 immune suppression status at study recruitment and being on a NVP based regimen. Early initiation of ART and phasing out NVP-based regimen might improve viral load suppression in children. In addition, children with a history of TB may need focused measures to maximize virological suppression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-021-06459-z","type":"journal-article","created":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T10:04:06Z","timestamp":1627898646000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["HIV virological non-suppression and its associated factors in children on antiretroviral therapy at a major treatment centre in Southern Ghana: a cross-sectional study"],"prefix":"10.1186","volume":"21","author":[{"given":"Adwoa K. A.","family":"Afrane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bamenla Q.","family":"Goka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorna","family":"Renner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred E.","family":"Yawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yakubu","family":"Alhassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth N.","family":"Owiafe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth","family":"Agyeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwamena W. C.","family":"Sagoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Awewura","family":"Kwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,2]]},"reference":[{"key":"6459_CR1","unstructured":"History of HIV and AIDS overview | Avert. https:\/\/www.avert.org\/professionals\/history-hiv-aids\/overview (Accessed 26 Dec 2019)."},{"key":"6459_CR2","unstructured":"HIV\/AIDS Facts, Prevention, Signs, Symptoms & Medications. eMedicineHealth. https:\/\/www.emedicinehealth.com\/hivaids\/article_em.htm (Accessed 26 Dec 2019)."},{"issue":"1","key":"6459_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2431-7-13","volume":"7","author":"A Reddi","year":"2007","unstructured":"Reddi A, Leeper SC, Grobler AC, Geddes R, France KH, Dorse GL, et al. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa. BMC Pediatr. 2007;7(1):13. https:\/\/doi.org\/10.1186\/1471-2431-7-13.","journal-title":"BMC Pediatr"},{"issue":"4","key":"6459_CR4","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1542\/peds.2007-0273","volume":"119","author":"Aids C on P, Health S on IC","year":"2007","unstructured":"Aids C on P, Health S on IC. Increasing antiretroviral drug access for children with HIV infection. Pediatrics. 2007;119(4):838\u201345. https:\/\/doi.org\/10.1542\/peds.2007-0273.","journal-title":"Pediatrics"},{"key":"6459_CR5","unstructured":"WHO | Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations. WHO. http:\/\/www.who.int\/hiv\/pub\/guidelines\/keypopulations-2016\/en\/ (Accessed 20 Sep 2016)."},{"key":"6459_CR6","volume-title":"2016 HIV Sentinel Survey Report","author":"National AIDS\/STI Control Programme, Ghana Health Service","year":"2016","unstructured":"National AIDS\/STI Control Programme, Ghana Health Service. 2016 HIV Sentinel Survey Report 2016."},{"key":"6459_CR7","unstructured":"talent maphosa. 6. hiv antiretroviral resistance. 14:27:59 UTC.https:\/\/www.slideshare.net\/talentmaphosa1\/6-hiv-antiretroviral-resistance (Accessed 26 Dec 2019)."},{"issue":"1","key":"6459_CR8","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1186\/s12879-017-2428-3","volume":"17","author":"L Bulage","year":"2017","unstructured":"Bulage L, Ssewanyana I, Nankabirwa V, Nsubuga F, Kihembo C, Pande G, et al. Factors associated with virological non-suppression among HIV-positive patients on antiretroviral therapy in Uganda, august 2014\u2013July 2015. BMC Infect Dis. 2017;17(1):326. https:\/\/doi.org\/10.1186\/s12879-017-2428-3.","journal-title":"BMC Infect Dis"},{"key":"6459_CR9","unstructured":"WHO | Global action plan for HIV drug resistance 2016-2021. https:\/\/www.who.int\/hiv\/pub\/drugresistance\/hiv-drug-resistance-brief-2016\/en\/ (Accessed 13 Feb 2019)."},{"issue":"10","key":"6459_CR10","doi-asserted-by":"publisher","first-page":"e588","DOI":"10.1016\/S2352-3018(18)30173-5","volume":"5","author":"RL Hamers","year":"2018","unstructured":"Hamers RL, de Wit TFR, Holmes CB. HIV drug resistance in low-income and middle-income countries. Lancet HIV. 2018;5(10):e588\u201396. https:\/\/doi.org\/10.1016\/S2352-3018(18)30173-5.","journal-title":"Lancet HIV"},{"issue":"1","key":"6459_CR11","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/1471-2334-12-197","volume":"12","author":"T Bacha","year":"2012","unstructured":"Bacha T, Tilahun B, Worku A. Predictors of treatment failure and time to detection and switching in HIV-infected Ethiopian children receiving first line anti-retroviral therapy. BMC Infect Dis. 2012;12(1):197. https:\/\/doi.org\/10.1186\/1471-2334-12-197.","journal-title":"BMC Infect Dis"},{"issue":"5","key":"6459_CR12","doi-asserted-by":"publisher","first-page":"e1134","DOI":"10.1542\/peds.2006-3503","volume":"120","author":"B Janssens","year":"2007","unstructured":"Janssens B, Raleigh B, Soeung S, Akao K, Te V, Gupta J, et al. Effectiveness of highly active antiretroviral therapy in HIV-positive children: evaluation at 12 months in a routine program in Cambodia. Pediatrics. 2007;120(5):e1134\u201340. https:\/\/doi.org\/10.1542\/peds.2006-3503.","journal-title":"Pediatrics"},{"issue":"11","key":"6459_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0200242","volume":"13","author":"J Kadima","year":"2018","unstructured":"Kadima J, Patterson E, Mburu M, Blat C, Nyanduko M, Bukusi EA, et al. Adoption of routine virologic testing and predictors of virologic failure among HIV-infected children on antiretroviral treatment in western Kenya. PLoS One. 2018;13(11):e0200242. https:\/\/doi.org\/10.1371\/journal.pone.0200242.","journal-title":"PLoS One"},{"issue":"9","key":"6459_CR14","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1093\/jac\/dkv143","volume":"70","author":"M Rup\u00e9rez","year":"2015","unstructured":"Rup\u00e9rez M, Pou C, Maculuve S, Cede\u00f1o S, Luis L, Rodr\u00edguez J, et al. Determinants of virological failure and antiretroviral drug resistance in Mozambique. J Antimicrob Chemother. 2015;70(9):2639\u201347. https:\/\/doi.org\/10.1093\/jac\/dkv143.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"6459_CR15","doi-asserted-by":"publisher","first-page":"e00296","DOI":"10.1002\/prp2.296","volume":"5","author":"S Yassin","year":"2017","unstructured":"Yassin S, Gebretekle GB. Magnitude and predictors of antiretroviral treatment failure among HIV-infected children in fiche and Kuyu hospitals, Oromia region, Ethiopia: a retrospective cohort study. Pharmacol Res Perspect. 2017;5(1):e00296. https:\/\/doi.org\/10.1002\/prp2.296.","journal-title":"Pharmacol Res Perspect"},{"issue":"12","key":"6459_CR16","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1097\/QAD.0b013e32833a2507","volume":"24","author":"S Komati","year":"2010","unstructured":"Komati S, Shaw PA, Stubbs N, Mathibedi MJ, Malan L, Sangweni P, et al. Tuberculosis risk factors and mortality for HIV infected persons receiving antiretroviral therapy in South Africa. AIDS Lond Engl. 2010;24(12):1849\u201355. https:\/\/doi.org\/10.1097\/QAD.0b013e32833a2507.","journal-title":"AIDS Lond Engl"},{"issue":"1","key":"6459_CR17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/jpids\/piu032","volume":"4","author":"P Costenaro","year":"2015","unstructured":"Costenaro P, Penazzato M, Lundin R, Rossi G, Massavon W, Patel D, et al. Predictors of treatment failure in HIV-positive children receiving combination antiretroviral therapy: cohort data from Mozambique and Uganda. J Pediatr Infect Dis Soc. 2015;4(1):39\u201348. https:\/\/doi.org\/10.1093\/jpids\/piu032.","journal-title":"J Pediatr Infect Dis Soc"},{"issue":"7","key":"6459_CR18","doi-asserted-by":"publisher","first-page":"e68995","DOI":"10.1371\/journal.pone.0068995","volume":"8","author":"P Pillay","year":"2013","unstructured":"Pillay P, Ford N, Shubber Z, Ferrand RA. Outcomes for Efavirenz versus Nevirapine-containing regimens for treatment of HIV-1 infection: a systematic review and meta-analysis. PLoS One. 2013;8(7):e68995. https:\/\/doi.org\/10.1371\/journal.pone.0068995.","journal-title":"PLoS One"},{"issue":"10","key":"6459_CR19","doi-asserted-by":"publisher","first-page":"696","DOI":"10.7196\/SAMJ.7807","volume":"104","author":"EM Mgelea","year":"2014","unstructured":"Mgelea EM, Kisenge R, Aboud S. Detecting virological failure in HIV-infected Tanzanian children. SAMJ South Afr Med J. 2014;104(10):696\u20139. https:\/\/doi.org\/10.7196\/SAMJ.7807.","journal-title":"SAMJ South Afr Med J"},{"key":"6459_CR20","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1097\/01.qai.0000147522.34369.12","volume":"38","author":"PT Nieuwkerk","year":"2005","unstructured":"Nieuwkerk PT, Oort FJ. Self-reported adherence to antiretroviral therapy for HIV-1 infection and virologic treatment response: a meta-analysis. J Acquir Immune Defic Syndr 1999. 2005;38:445\u20138.","journal-title":"J Acquir Immune Defic Syndr 1999"},{"issue":"16","key":"6459_CR21","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1097\/00002030-200111090-00006","volume":"15","author":"R Gross","year":"2001","unstructured":"Gross R, Bilker WB, Friedman HM, Strom BL. Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. AIDS Lond Engl. 2001;15(16):2109\u201317. https:\/\/doi.org\/10.1097\/00002030-200111090-00006.","journal-title":"AIDS Lond Engl"},{"issue":"8","key":"6459_CR22","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1089\/apc.2007.0110","volume":"22","author":"SL Marhefka","year":"2008","unstructured":"Marhefka SL, Koenig LJ, Allison S, Bachanas P, Bulterys M, Bettica L, et al. Family experiences with pediatric antiretroviral therapy: responsibilities, barriers, and strategies for remembering medications. AIDS Patient Care STDs. 2008;22(8):637\u201347. https:\/\/doi.org\/10.1089\/apc.2007.0110.","journal-title":"AIDS Patient Care STDs"},{"issue":"5","key":"6459_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0036737","volume":"7","author":"JE Haberer","year":"2012","unstructured":"Haberer JE, Kiwanuka J, Nansera D, Ragland K, Mellins C, Bangsberg DR. Multiple measures reveal antiretroviral adherence successes and challenges in HIV-infected Ugandan children. PLoS One. 2012;7(5):e36737. https:\/\/doi.org\/10.1371\/journal.pone.0036737.","journal-title":"PLoS One"},{"issue":"1","key":"6459_CR24","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s41182-019-0135-z","volume":"47","author":"J Natukunda","year":"2019","unstructured":"Natukunda J, Kirabira P, Ong KIC, Shibanuma A, Jimba M. Virologic failure in HIV-positive adolescents with perfect adherence in Uganda: a cross-sectional study. Trop Med Health. 2019;47(1):8. https:\/\/doi.org\/10.1186\/s41182-019-0135-z.","journal-title":"Trop Med Health"},{"key":"6459_CR25","unstructured":"About us \u2013 Brief History. http:\/\/kbth.gov.gh\/brief-history\/. Accessed 3 Jan 2019."},{"key":"6459_CR26","unstructured":"Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing Hiv Infection: Recommendations for a Public Health Approach. 2016 http:\/\/www.deslibris.ca\/ID\/10089566 (Accessed 11 Apr 2019)."},{"key":"6459_CR27","doi-asserted-by":"crossref","unstructured":"Heinisch O. Cochran, W. G.: sampling techniques, 2. Aufl. John Wiley and Sons, New York, London 1963. Preis s. Biom Z. 1965;7:203.","DOI":"10.1002\/bimj.19650070312"},{"key":"6459_CR28","doi-asserted-by":"crossref","unstructured":"Nichols JS, Kyriakides TC, Antwi S, Renner L, Lartey M, Seaneke OA, et al. High prevalence of non-adherence to antiretroviral therapy among undisclosed HIV-infected children in Ghana. AIDS Care. 2019;31(1):25\u201334. Available from: https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/09540121.2018.1524113.\u00a0Accessed 5 Feb 2019.\u00a0","DOI":"10.1080\/09540121.2018.1524113"},{"key":"6459_CR29","unstructured":"WHO | Antiretroviral therapy of HIV infection in infants and children: towards universal access. WHO. http:\/\/www.who.int\/hiv\/pub\/guidelines\/art\/en\/ (Accessed 23 May 2017)."},{"key":"6459_CR30","unstructured":"Ending AIDS: progress towards the 90\u201390\u201390 targets | UNAIDS. http:\/\/www.unaids.org\/en\/resources\/documents\/2017\/20170720_Global_AIDS_update_2017 (Accessed 14 Feb 2019)."},{"issue":"Suppl 2","key":"6459_CR31","first-page":"S151","volume":"28","author":"JD Tucker","year":"2014","unstructured":"Tucker JD, Bien CH, Easterbrook PJ, Doherty MC, Penazzato M, Vitoria M, et al. Optimal strategies for monitoring response to antiretroviral therapy in HIV-infected adults, adolescents, children and pregnant women: a systematic review. AIDS Lond Engl. 2014;28(Suppl 2):S151\u201360.","journal-title":"AIDS Lond Engl"},{"issue":"12","key":"6459_CR32","doi-asserted-by":"publisher","first-page":"e0144057","DOI":"10.1371\/journal.pone.0144057","volume":"10","author":"AT Makadzange","year":"2015","unstructured":"Makadzange AT, Higgins-Biddle M, Chimukangara B, Birri R, Gordon M, Mahlanza T, et al. Clinical, virologic, immunologic outcomes and emerging HIV drug resistance patterns in children and adolescents in public ART Care in Zimbabwe. PLoS One. 2015;10(12):e0144057. https:\/\/doi.org\/10.1371\/journal.pone.0144057.","journal-title":"PLoS One"},{"issue":"2","key":"6459_CR33","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3851\/IMP3349","volume":"25","author":"DF Bavaro","year":"2020","unstructured":"Bavaro DF, Di Carlo D, Rossetti B, Bruzzone B, Vicenti I, Pontali E, et al. Pretreatment HIV drug resistance and treatment failure in non-Italian HIV-1-infected patients enrolled in ARCA. Antivir Ther. 2020;25(2):61\u201371. https:\/\/doi.org\/10.3851\/IMP3349.","journal-title":"Antivir Ther"},{"issue":"2","key":"6459_CR34","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1089\/aid.2018.0202","volume":"35","author":"B Chimukangara","year":"2019","unstructured":"Chimukangara B, Kharsany ABM, Lessells RJ, Naidoo K, Rhee S-Y, Manasa J, et al. Moderate-to-high levels of pretreatment HIV drug resistance in KwaZulu-Natal Province, South Africa. AIDS Res Hum Retrovir. 2019;35(2):129\u201338. https:\/\/doi.org\/10.1089\/aid.2018.0202.","journal-title":"AIDS Res Hum Retrovir"},{"issue":"7","key":"6459_CR35","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1089\/apc.2018.0020","volume":"32","author":"SM McCluskey","year":"2018","unstructured":"McCluskey SM, Lee GQ, Kamelian K, Kembabazi A, Musinguzi N, Bwana MB, et al. Increasing prevalence of HIV pretreatment drug resistance in women but not men in rural Uganda during 2005\u20132013. AIDS Patient Care STDs. 2018;32(7):257\u201364. https:\/\/doi.org\/10.1089\/apc.2018.0020.","journal-title":"AIDS Patient Care STDs"},{"issue":"3","key":"6459_CR36","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1093\/jac\/dky486","volume":"74","author":"PC Aulicino","year":"2019","unstructured":"Aulicino PC, Zapiola I, Kademian S, Valle MM, Fernandez Giuliano S, Toro R, et al. Pre-treatment drug resistance and HIV-1 subtypes in infants from Argentina with and without exposure to antiretroviral drugs for prevention of mother-to-child transmission. J Antimicrob Chemother. 2019;74(3):722\u201330. https:\/\/doi.org\/10.1093\/jac\/dky486.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"6459_CR37","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/S1473-3099(17)30702-8","volume":"18","author":"RK Gupta","year":"2018","unstructured":"Gupta RK, Gregson J, Parkin N, Haile-Selassie H, Tanuri A, Forero LA, et al. HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis. Lancet Infect Dis. 2018;18(3):346\u201355. https:\/\/doi.org\/10.1016\/S1473-3099(17)30702-8.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"6459_CR38","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/QAD.0000000000001273","volume":"31","author":"L Muri","year":"2017","unstructured":"Muri L, Gamell A, Ntamatungiro AJ, Glass TR, Luwanda LB, Battegay M, et al. Development of HIV drug resistance and therapeutic failure in children and adolescents in rural Tanzania: an emerging public health concern. AIDS Lond Engl. 2017;31(1):61\u201370. https:\/\/doi.org\/10.1097\/QAD.0000000000001273.","journal-title":"AIDS Lond Engl"},{"key":"6459_CR39","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/QAI.0b013e31814278c0","volume":"46","author":"MR Kamya","year":"2007","unstructured":"Kamya MR, Mayanja-Kizza H, Kambugu A, Bakeera-Kitaka S, Semitala F, Mwebaze-Songa P, et al. Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy. JAIDS J Acquir Immune Defic Syndr. 2007;46:187\u201393.","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"key":"6459_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0116144","volume":"10","author":"K Jobanputra","year":"2015","unstructured":"Jobanputra K, Parker LA, Azih C, Okello V, Maphalala G, Kershberger B, et al. Factors associated with Virological failure and suppression after enhanced adherence Counselling, in children, adolescents and adults on antiretroviral therapy for HIV in Swaziland. PLOS ONE. 2015;10:e0116144.","journal-title":"PLOS ONE"},{"issue":"11","key":"6459_CR41","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1097\/INF.0000000000001672","volume":"36","author":"AE Njom Nlend","year":"2017","unstructured":"Njom Nlend AE, Motaze AN, Ndiang ST, Fokam J. Predictors of Virologic failure on first-line antiretroviral therapy among children in a referral pediatric center in Cameroon. Pediatr Infect Dis J. 2017;36(11):1067\u201372. https:\/\/doi.org\/10.1097\/INF.0000000000001672.","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"6459_CR42","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/1471-2334-9-81","volume":"9","author":"L Ahoua","year":"2009","unstructured":"Ahoua L, Guenther G, Pinoges L, Anguzu P, Chaix M-L, Le Tiec C, et al. Risk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIV-positive adults treated in rural northwestern Uganda. BMC Infect Dis. 2009;9(1):81. https:\/\/doi.org\/10.1186\/1471-2334-9-81.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"6459_CR43","doi-asserted-by":"publisher","first-page":"78","DOI":"10.20546\/ijcmas.2017.601.010","volume":"6","author":"M Rajian","year":"2017","unstructured":"Rajian M, Gill PS, Chaudhary U. Effect of tuberculosis co infection on virological failure in HIV patients on first line of highly active antiretroviral therapy. Int J Curr Microbiol Appl Sci. 2017;6(1):78\u201381. https:\/\/doi.org\/10.20546\/ijcmas.2017.601.010.","journal-title":"Int J Curr Microbiol Appl Sci"},{"issue":"9","key":"6459_CR44","first-page":"708","volume":"94","author":"RH Goldschmidt","year":"2016","unstructured":"Goldschmidt RH, Chu C, Dong BJ. Initial Management of Patients with HIV infection. Am Fam Physician. 2016;94(9):708\u201316.","journal-title":"Am Fam Physician"},{"issue":"1","key":"6459_CR45","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1186\/s12879-016-1952-x","volume":"16","author":"J Izudi","year":"2016","unstructured":"Izudi J, Alioni S, Kerukadho E, Ndungutse D. Virological failure reduced with HIV-serostatus disclosure, extra baseline weight and rising CD4 cells among HIV-positive adults in northwestern Uganda. BMC Infect Dis. 2016;16(1):614. https:\/\/doi.org\/10.1186\/s12879-016-1952-x.","journal-title":"BMC Infect Dis"},{"key":"6459_CR46","doi-asserted-by":"publisher","unstructured":"Bayu B, Tariku A, Bulti AB, Habitu YA, Derso T, Teshome DF. Determinants of virological failure among patients on highly active antiretroviral therapy in University of Gondar Referral Hospital, Northwest Ethiopia: a case-control study. HIVAIDS - Res Palliat Care. 2017. https:\/\/doi.org\/10.2147\/HIV.S139516.","DOI":"10.2147\/HIV.S139516"},{"issue":"3","key":"6459_CR47","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1097\/QAD.0000000000000032","volume":"28","author":"R Legarth","year":"2014","unstructured":"Legarth R, Omland LH, Kronborg G, Larsen CS, Pedersen C, Gerstoft J, et al. Educational attainment and risk of HIV infection, response to antiretroviral treatment, and mortality in HIV-infected patients. AIDS Lond Engl. 2014;28(3):387\u201396. https:\/\/doi.org\/10.1097\/QAD.0000000000000032.","journal-title":"AIDS Lond Engl"},{"key":"6459_CR48","volume-title":"Predictors of Virological failure among children infected with HIV-1 on Haart at KATH","author":"E Mensah","year":"2017","unstructured":"Mensah E. Predictors of Virological failure among children infected with HIV-1 on Haart at KATH. 2017. http:\/\/ir.knust.edu.gh:8080\/handle\/123456789\/10001 (Accessed 4 Feb 2019)."},{"key":"6459_CR49","unstructured":"Measurement Issues in Using Pharmacy Records to Calculate Adherence to Antiretroviral Drugs: HIV Clinical Trials: Vol 14, No 2. https:\/\/www.tandfonline.com\/doi\/abs\/10.1310\/hct1402-68 (Accessed 2 Feb 2019)."},{"issue":"6","key":"6459_CR50","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1089\/apc.2013.0276","volume":"28","author":"J Intasan","year":"2014","unstructured":"Intasan J, Bunupuradah T, Vonthanak S, Kosalaraksa P, Hansudewechakul R, Kanjanavanit S, et al. Comparison of adherence monitoring tools and correlation to virologic failure in a pediatric HIV clinical trial. AIDS Patient Care STDs. 2014;28(6):296\u2013302. https:\/\/doi.org\/10.1089\/apc.2013.0276.","journal-title":"AIDS Patient Care STDs"},{"key":"6459_CR51","unstructured":"Use of a prescription-based measure of antiretroviral therapy adherence to predict viral rebound in HIV-infected individuals with viral suppression - Cambiano - 2010 - HIV Medicine - Wiley Online Library. https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1111\/j.1468-1293.2009.00771.x. Accessed 2 Feb 2019."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06459-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-021-06459-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06459-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T10:04:51Z","timestamp":1627898691000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-021-06459-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,2]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["6459"],"URL":"https:\/\/doi.org\/10.1186\/s12879-021-06459-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-448212\/v1","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,2]]},"assertion":[{"value":"21 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval (KBTH-IRB\/ 00060\/2017) was obtained from the Institutional Review Board of Korle Bu Teaching Hospital, Accra, Ghana. An informed consent was obtained from parents or legal guardians for each minor participant prior to enrolment to participate in the study. All procedures performed involving study participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare that there are no competing interests<b>.<\/b>","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"731"}}